Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy. - Wikidata - wikimedia - TriplyDB

Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy.

Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy.

http://www.wikidata.org/entity/Q44384154

about

First-line drugs inhibiting the renin angiotensin system versus other first-line antihypertensive drug classes for hypertension Calcium channel blockers versus other classes of drugs for hypertension Angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists for preventing the progression of diabetic kidney disease Standards of medical care in diabetes--2012 Diabetes mellitus as a compelling indication for use of renin angiotensin system blockers: systematic review and meta-analysis of randomized trials The effects of calcium channel blockers in the prevention of stroke in adults with hypertension: a meta-analysis of data from 273,543 participants in 31 randomized controlled trials Standards of medical care in diabetes--2013 A current evaluation of the safety of angiotensin receptor blockers and direct renin inhibitors Methods underpinning national clinical guidelines for hypertension: describing the evidence shortfall.Standards of medical care in diabetes--2010.Dual blockade of the renin-angiotensin system in diabetic nephropathy.Understanding the quality chasm for hypertension control in diabetes: a structured review of "co-maneuvers" used in clinical trials.BP, cardiovascular disease, and death in the Folic Acid for Vascular Outcome Reduction in Transplantation trial.Angiotensin receptor blockers and risk of myocardial infarction: systematic review.Ace inhibitor therapy for heart failure in patients with impaired renal function: a review of the literature.Comparative effectiveness of renin-angiotensin system blockers and other antihypertensive drugs in patients with diabetes: systematic review and bayesian network meta-analysis.Standards of medical care in diabetes--2011.Effects of ACEI/ARB in hypertensive patients with type 2 diabetes mellitus: a meta-analysis of randomized controlled studies.The value of irbesartan in the management of hypertension.Microalbuminuria and diabetic cardiovascular disease.Angiotensin receptor blockers in heart failure.Hypertension and the elderly: more than just blood pressure control.Long-term renal and cardiovascular outcomes in Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) participants by baseline estimated GFR.Angiotensin receptor blockers versus ACE inhibitors: prevention of death and myocardial infarction in high-risk populations.The prevention of cardiovascular disease in cancer survivors.Outpatient management of type 2 diabetic patients: a review of evidence-based literature.New bundled world: quality of care and readmission in diabetes patients Antihypertensive, antiproteinuric therapy and myocardial infarction and stroke prevention.Aliskiren suppresses the renin-angiotensin-aldosterone system and reduces blood pressure and albuminuria in elderly chronic kidney disease patients with hypertension.Renin-Angiotensin-Aldosterone System Blockade in Diabetic Nephropathy. Present Evidences.Losartan: a review of its use in stroke risk reduction in patients with hypertension and left ventricular hypertrophy.Therapeutic potential of angiotensin receptor blockers in hypertension.Managing hypertension in diabetic patients--focus on trandolapril/verapamil combination.Drug therapy recommendations from the 2005 ACC/AHA guidelines for treatment of chronic heart failure.Clinical trial update: focus on the ONTARGET study Diuretics: a modern day treatment option?Modification of cardiovascular risk in hemodialysis patients: an evidence-based review.Benefits of tight blood pressure control in diabetic patients with hypertension: importance of early and sustained implementation of effective treatment strategies Low-grade albuminuria and cardiovascular risk : what is the evidence?Preparing for the worst while hoping for the best: the relevance of hope in the heart failure illness trajectory.

P2860

Q24186647-A2617CB3-7D37-4949-8297-EC495DBB20CA Q24236584-D61553A8-E185-4931-BFD4-86B22E2C9B0A Q24244197-D3718D7C-357C-47DC-BD2B-7D07FCF0057B Q24632533-10ACC36E-9F09-4825-AF3D-5551233EF121 Q26766599-D1BA7464-2ADF-4A13-92F1-F88B3FCE251F Q28487721-568C7691-ED71-451E-892F-6EFB06A4F3C3 Q29620309-11B69943-F83F-4292-9878-E8CC673F50AD Q30432209-E0E2B61C-218A-4556-8FDD-EE07360F1D8F Q33239013-7D12B51E-4DF7-4951-A86C-C5B226B3425D Q33554238-CD35C19E-24AE-4914-8C50-0E20358CD512 Q33610694-5D29923E-136A-43C2-877C-08D49942894C Q33750286-5CE645B1-E6F8-4663-B998-6124774C4931 Q33814858-07B98791-2C9A-4EA3-B216-96F9FB740924 Q34081519-424D1765-04A1-4D05-9AC7-544629F59919 Q34244029-5F9CCD14-AF7D-4B19-BB0C-A54197CBF410 Q34380070-68B73064-D9C8-42F0-B727-66848C4C9EB7 Q34425055-4E801D1F-319F-4FF0-ADD8-105848F092FC Q34459963-2D908539-EA0B-4350-9A91-A6833423B9DB Q34609900-EBF279C7-7699-496E-835E-285944052F3A Q35197102-D1870865-DE77-4262-87C4-72BA25F2C26A Q35580150-B4E9CF33-9D89-4DAA-8559-FA2C7493B08C Q35767490-941343CE-B1A9-4957-A3EF-DEB5283D9F70 Q35995026-C384B500-4DD5-4452-A0D1-B9AB633C7068 Q36035236-68C2B1A1-06E9-43F4-9BC2-3A6614CBED3F Q36061056-AE67B1D3-B855-4819-9491-E5E77623B407 Q36133908-F3AD9132-8CA4-4B9F-A439-2ED8F3C441A4 Q36228948-E947E0A2-EF25-4694-AF6D-B79648713695 Q36255428-09097668-7B10-4810-9F7F-BED9FCB813FB Q36286798-87CEF577-109B-4C67-BDFC-A1D556A61D37 Q36329456-A20BD75C-3E2B-4B58-882B-E3873319FA8E Q36360341-EFEE026B-618B-4ABD-AC9C-5AC3E20E7556 Q36491825-BC7F50BB-9C02-4FEC-840D-8A54838FD223 Q36536275-D36A0511-E3C1-468B-90BB-334004FC7BC7 Q36559988-D5AB325A-D56B-4D4B-A980-F6004D49D470 Q36596857-B3DD3F04-95F9-4FA2-B4CF-92DD06848B79 Q36609875-94EA2411-AC63-4335-9629-BEBF3498AC75 Q36719781-44EB1E97-0DC0-4CC2-90D5-5C4512C55089 Q36783870-56FE23B5-6B1A-44F6-A5C2-37B6CC0B49C1 Q36799139-DE99F8B9-9548-4839-91ED-AD34F3FFE3D3 Q36839029-2D86A82B-710B-4E9F-8995-0B14A442EBE2

P2860

Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy.

http://www.wikidata.org/entity/Q44384154

description

2003 nî lūn-bûn

@nan

2003年の論文

@ja

2003年学术文章

@wuu

2003年学术文章

@zh

2003年学术文章

@zh-cn

2003年学术文章

@zh-hans

2003年学术文章

@zh-my

2003年学术文章

@zh-sg

2003年學術文章

@yue

2003年學術文章

@zh-hant

name

Cardiovascular outcomes in the ...... iabetes and overt nephropathy.

@en

Cardiovascular outcomes in the ...... iabetes and overt nephropathy.

@nl

type

label

Cardiovascular outcomes in the ...... iabetes and overt nephropathy.

@en

Cardiovascular outcomes in the ...... iabetes and overt nephropathy.

@nl

prefLabel

Cardiovascular outcomes in the ...... iabetes and overt nephropathy.

@en

Cardiovascular outcomes in the ...... iabetes and overt nephropathy.

@nl

P1433

Q44384154-FB66480C-4804-43B6-94BE-DB67F70E46F0

P1476

Q44384154-F094777D-A9DE-433C-AFFF-11A44E22E144

P2093

Q44384154-18299022-A3F4-4576-953B-58A21CA1C6BE

Q44384154-1EE4176F-E158-4F77-B95C-3E8D89416F9D

Q44384154-3D135FCF-E9AF-4A9D-BF9F-6EDDA2ACFA53

Q44384154-42A48935-2285-4C28-A0A9-B21A407B2801

Q44384154-471E7461-FB04-4C29-8175-12C9B74F354F

Q44384154-4A9E8EB7-63F9-4066-BE6C-1A54BFA4FEB8

Q44384154-4BE95DBF-20B6-44FD-842D-EBDEFFCFA151

Q44384154-617843B7-C29F-4344-BAD3-21EB1C62B920

Q44384154-6517AD37-A605-4950-8FDB-0F847BE97B82

Q44384154-80850BB3-BE54-4923-ADBA-476EE684BB43

P304

Q44384154-B646A04B-A510-4F5D-AADA-5FA1AA0DD2D5

P31

Q44384154-795FC780-9FAB-4578-8830-3C7DE346AF97

P356

Q44384154-A7943FAF-2C0E-448D-9ADD-28F083DEBA7A

P407

Q44384154-B13A11EE-AF8E-4CFD-BE2D-48B364D0D679

P433

Q44384154-C6E4CB9D-6AD6-448A-95D5-2BCAA72C90C6

P478

Q44384154-4A14018E-E76A-417F-82C1-1C51C173B63B

P577

Q44384154-AAE76718-8DAB-4529-977B-ECFDB98F3039

P698

Q44384154-F2252664-1DDD-4B75-99C6-8F8AEC6D0EE8

P921

Q44384154-017B9773-5C2B-41D8-9381-CC4D67292474

Q44384154-16760BB8-06FD-4FFD-B3D8-86C8E566E523

Q44384154-96BE948C-2C65-40F0-AAEE-183ADAE293C8

P356

0003-4819-138-7-200304010-00010

P1433

Annals of Internal Medicine

P1476

Cardiovascular outcomes in the ...... iabetes and overt nephropathy.

@en

P2093

Bernard M Wolfe

http://www.w3.org/2001/XMLSchema#string

Chirag R Parikh

http://www.w3.org/2001/XMLSchema#string

Donald Hricik

http://www.w3.org/2001/XMLSchema#string

Edmund J Lewis

http://www.w3.org/2001/XMLSchema#string

Enric Esmatjes

http://www.w3.org/2001/XMLSchema#string

Francesco Locatelli

http://www.w3.org/2001/XMLSchema#string

Irbesartan Diabetic Nephropathy Trial. Collaborative Study Group

http://www.w3.org/2001/XMLSchema#string

Itamar Raz

http://www.w3.org/2001/XMLSchema#string

Jean-Lucien Rouleau

http://www.w3.org/2001/XMLSchema#string

Jerome G Porush

http://www.w3.org/2001/XMLSchema#string

P304

542-549

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.7326/0003-4819-138-7-200304010-00010

http://www.w3.org/2001/XMLSchema#string

P407

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

138

http://www.w3.org/2001/XMLSchema#string

P577

2003-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

12667024

http://www.w3.org/2001/XMLSchema#string

P921

Aparato circulatorio

type-2 diabetes